• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Sunday, October 5, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Systemic sclerosis-associated interstitial lung disease focus of latest clinical practice guideline

Bioengineer by Bioengineer
November 8, 2023
in Health
Reading Time: 2 mins read
0
Clinical Practice Guideline
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

In patients with systemic sclerosis (SSc), a rare connective tissue disease, interstitial lung disease contributes to 35 percent of deaths. Published recently in the American Journal of Respiratory and Critical Care Medicine, the latest American Thoracic Society Clinical Practice Guideline makes a number of recommendations. One recommendation expands antifibrotic treatment to all patients with systemic sclerosis associated with ILD (SSc-ILD), not just those with progressive disease.

Clinical Practice Guideline

Credit: ATS

In patients with systemic sclerosis (SSc), a rare connective tissue disease, interstitial lung disease contributes to 35 percent of deaths. Published recently in the American Journal of Respiratory and Critical Care Medicine, the latest American Thoracic Society Clinical Practice Guideline makes a number of recommendations. One recommendation expands antifibrotic treatment to all patients with systemic sclerosis associated with ILD (SSc-ILD), not just those with progressive disease.

Watch the explainer video.

Lead guidelines chair and editor, Ganesh Raghu, M.D., ATSF, noted the timeliness of the recommendations given the many immune modulating agents clinicians already use to treat connective tissue diseases, including SSc. “The need to provide evidence-based clinical practice guideline was evident,” he said.

It was with this in mind that the 24-member international expert panel (that included pulmonologists, rheumatologists, methodologists and patients with SSc) convened. Using the thorough, evidence-based Grading of Recommendations, Assessment, Development and Evaluation or GRADE framework, the expert panel made the following recommendations and suggestions for treating patients with SSc-ILD:

1.We recommend using mycophenolate to treat patients with SSc-ILD (strong recommendation, very low-quality evidence).

 

2.We suggest using the following medications to treat patients with SSc-ILD:

i :   cyclophosphamide (conditional recommendation, low- quality evidence).

ii :  nintedanib  (conditional recommendation, very low-quality evidence).

iii:   rituximab  (conditional recommendation, very low-quality evidence).

iv:   tocilizumab  (conditional recommendation, very low-quality evidence).

v:   the combination of nintedanib plus mycophenolate (conditional recommendation, very low-quality evidence).

 

3. We recommend further research into the safety and efficacy of pirfenidone  alone or in combination with mycophenolate  to treat patients with SSc-ILD.

Regarding treatment with antifibrotics like nintedanib and pirfenidone, “We emphasize the importance of the shared decision process with patients and physicians, especially for the recommendations that are conditional,” added Dr. Raghu.

To read the latest clinical practice guideline on systemic sclerosis-associated interstitial lung disease in its entirety, visit us online.

For ATS guideline implementation tools and derivatives, go here.
 

To learn about clinical trials recruiting patients with SSc-ILD, visit the ATS Clinical Trials Resources page. *The ATS does not endorse any trial listed.

 



Journal

American Journal of Respiratory and Critical Care Medicine

Method of Research

Systematic review

Subject of Research

People

Article Title

Treatment of Systemic Sclerosis-associated Interstitial Lung Disease: Evidence-based Recommendations. An Official American Thoracic Society Clinical Practice Guideline

Share12Tweet8Share2ShareShareShare2

Related Posts

Supporting Caregivers of COPD Patients: Key Insights

October 5, 2025

Evaluating Mid-Upper Arm Circumference for Child Thinness

October 5, 2025

GDI-PMNet Enables Joint Prediction of Glioma Markers

October 5, 2025

Racial Disparities in Anticoagulant Use for Atrial Fibrillation

October 5, 2025

POPULAR NEWS

  • New Study Reveals the Science Behind Exercise and Weight Loss

    New Study Reveals the Science Behind Exercise and Weight Loss

    94 shares
    Share 38 Tweet 24
  • New Study Indicates Children’s Risk of Long COVID Could Double Following a Second Infection – The Lancet Infectious Diseases

    92 shares
    Share 37 Tweet 23
  • Physicists Develop Visible Time Crystal for the First Time

    75 shares
    Share 30 Tweet 19
  • New Insights Suggest ALS May Be an Autoimmune Disease

    70 shares
    Share 28 Tweet 18

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Supporting Caregivers of COPD Patients: Key Insights

Exploring Plastid Genome Traits in Saururaceae

Evaluating Mid-Upper Arm Circumference for Child Thinness

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 62 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.